Journals / MN Kardiyoloji / 2000 / Cilt: 7 - Sayı: 2

Blood estradiol concentrations in premenopausal women with coronary artery disease

İskemik kalp hastalıklı premenopozal kadınlarda serum östradiol konsantrasyonu

Pages
120–124
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

CONCLUSION: These data support the fact that low estradiol concentrations in menstruating women with coronary heart disease, may be a pathogenic factor.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:AIM: It is very well known that estrogen has proved benefit in ischemic heart disease in premenopausal women and, thus the menstruating women have a lower risk of acute myocardial infarction in comparison with the men of the same age group.
📊
Key Findings & Data:METHOD: We compared 38 premenopausal women with coronary artery disease and 20 healthy women, whose ages and risk factors were similar, in terms of TC, HDL, LDL, TG, age, blood pressure, number of pregnancy, usage of oral contraceptives and risk factors like .diabetes, smoking and family history.
💡
Conclusion & Impact:CONCLUSION: These data support the fact that low estradiol concentrations in menstruating women with coronary heart disease, may be a pathogenic factor.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Premenopoz · Koroner hastalık · Östradiol

Abstract

AIM: It is very well known that estrogen has proved benefit in ischemic heart disease in premenopausal women and, thus the menstruating women have a lower risk of acute myocardial infarction in comparison with the men of the same age group. We investigated if blood estrogen concentrations were lower in premenopausal women suffering coronary artery disease. METHOD: We compared 38 premenopausal women with coronary artery disease and 20 healthy women, whose ages and risk factors were similar, in terms of TC, HDL, LDL, TG, age, blood pressure, number of pregnancy, usage of oral contraceptives and risk factors like .diabetes, smoking and family history. Plasma levels of estradiol and progesterone were measured on the 5-8th day of ovulation, because their concentrations rise in the second half of the menstruel cycle. Menstruel cycle regularity and follicle stimulating hormone levels were also assessed. RESULTS: Plasma estradiol concentrations were significantly lower (392±113.1 pmol/l and 267±97.4 pmol/l respectively; p=0.04), follicle stimulating hormone (3.8±0.9 IU/l and 4.6±0.7 IU/l respectively; p=0.04) and progesterone (41.8±22.9 and 33.4±17 nmol/l respectively; p=0.05) were higher in the premenopausal women with ischemic heart disease when compared with control group. CONCLUSION: These data support the fact that low estradiol concentrations in menstruating women with coronary heart disease, may be a pathogenic factor.

Özet

AMAÇ: Premenopozal kadınlarda , iskemik kalp hastalığına karşı östrojenin yararlı etkileri olduğu ve bu nedenle de, aynı yaş grubundaki erkek cinsiyete oranla menstrual siklusu devam eden kadınların akut miyokard infarktüsü için daha düşük risk taşıdıkları bilinmektedir. Bu bilgi ışığında koroner kalp hastalığı olan premenopozal kadınlarda serum östrojen konsantrasyonunun düşük olabileceği varsayımını araştırmak istedik. YÖNTEM: Yaş ve koroner risk faktörleri uyumlu 38 premenopozal koroner hastası kadın ile 20 sağlıklı kadını karşılaştırdık. Her İki grubu: TK, HDL, LDL, TG, yaş, kan basıncı, diyabet, aile hikayesi, sigara, gebelik sayısı, oral kontraseptif kullanımı bakımından inceledik. Plazma Östradiol ve progesteron düzeyi menstrual siklusun ikinci yarısında yükseldiği için takriben ovulasyondan 5-8 gün sonra ölçümleri yapıldı. Siklus düzenliliği ve folikül sitimüle edici hormon tayini yapıldı. BULGULAR: Plazma Östradiol konsantrasyonu kontrol grubu ile karşılaştırdığımızda, iskemik kalp hastalıklı premenopozal kadınlarda önemli derecede düşük (392.7±113.1 pmol/l ve 267.3±97.4 pmol/l sırasıyla; p=0.03), folikül sitümüle edici hormon ve progesteron düzeyi ise (3.8±0.9 İÜ/l ve 4.6±0.7 İÜ/l p=0.04), (41.8±22.9 ve 33.4±17 nmol/l; p=0.05)yüksek bulundu. SONUÇ: Bu veriler menstrual siklusu aktif olan koroner kalp hastası kadınlarda düşük Östradiol konsantrasyonunun patojenik bir faktör olabileceği varsayımını desteklemektedir.

🔖

Cite This Article

DEMİR, İ., ERMİŞ, C., DEMİR, F., YALÇINKAYA, S., SEMİZ, E., ERSEL, F. (2000). Blood estradiol concentrations in premenopausal women with coronary artery disease. MN Kardiyoloji, Cilt: 7 - Sayı: 2, 120–124. https://ajindex.com/articles/298136

References (4)

  1. Eaker ED, Chesebro JH, Sacks FM, Wenger NK, Whisnant JP. Cardiovasculer disease in woman. Circulation 1993; 88:1999. Eaker ED.Castelli WP. Coronary heart disease and its risk factors among women in the Framingham Study. Coronary Heart Disease in Woman. Bethesda, Md: National, Heart, Lung, and Blood Institute, National Institutes of Health; 1987.
  2. Lerner DJ, Kannel WB. Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population. Am Heart J 1986, 111: 383-90
  3. Stampfer MJ, Golditz CA, Willet WC, Manşon JE, Rosner B, Speizer FE. Postmenopausal estrogen therapy and cardiovascular disease. N Eng J Med 1991, 325: 756-62
  4. Grodstein F, Stampfer MJ. Estrogen for women at varying risk of coronary disease. Maturitas 1998; 30:19 Abu-Halawa SA, Thompson K, Kirkeeide RL, Vaughn WK, Rosales O, Fujisi K, Schroth G, Smalling R, Anderson HV. Estrogen replacement therapy and outcome of coronary balloon angioplasty in postmenopausal women. Am J Cardiol 1998; 82:409. Gillian DM, Badar DM.Panza JA, Ouyyumi AA, Cannon RO. Acute vascular effects of estrogen in postmenopausal woman. Circulation 1994; 90:786. de Ziegler D. Cardiovascular physiopathology of ovarian hormones. Schweiz Rundsch Med Prax 1997; 86:138. Barrett-Connor E, Stuenkel C. Hormones and heart disease in women: Heart and Estrogen Progestin Replacement Study in perspective. J Clin Endocrinol Metab 1999; 84:1848. Tremollieres FA, Pouilles JM, Cauneille C, Ribot C. Coronary heart disease risk factors and menopause: a study in 1684 French women. Atherosclerosis 1999; 142:415. Herrington DM, Fong J, Sempos CT, Black DM, Schrott HG, Rautaharju P, Bachorik PS, Blumenthal R, Khan S, Wenger NK. Comparison of the Heart and Estrogen/Progestin Replacement Study (HERS) cohort with women with coronary disease from the National Health and Nutrition Examination Survey III (NHANES III). Am Heart J 1998; 136:115. 1 Limacher MC. The role of hormone replacement therapy in preventing coronary artery disease in women. Curr Opin Cardiol 1998; 13:139. Stampfer MJ, Golditz GA, Willet WC. Menapause and heart disease: a review. Ann NY Acad Sci 1990; 592:193. Knopp RH, Zhu X, Bohet B. Effects of estrogens on lipoprotein metabolism and cardiovascular disease in women. Atherosclerosis 1994; 110:83. Henderson BE, Paganini-Hill A, Ross RK. Estrogen replacement therapy and protection from acute myocardial infarction. Am J Obstet Gynecol 1988; 159:312. Sullivan JM.Vander.Zwang R, Lemp GF, H